Truist Lowers Neurocrine Biosciences, Inc.’s (NBIX) PT Following 2026 Outlook Update

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Oversold Pharma Stocks to Buy Now.

Truist Lowers Neurocrine Biosciences, Inc.'s (NBIX) PT Following 2026 Outlook Update

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the most oversold stocks.

TheFly reported on February 17 that Truist reduced its price target on NBIX to $140 from $169 and maintained a Buy rating on the stock. The increase came after management’s 2026 projection, and the company’s fourth-quarter results were included in the firm’s financial model.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its fourth-quarter and full-year 2025 financial results earlier on February 11, which show strong top-line growth. According to the report, overall net product sales increased by 29% and 22% year over year to $798.3 million in Q4 and $2.83 billion for the entire year, respectively.

INGREZZA generated $657.5 million in fourth-quarter sales and $2.51 billion for the full year, reflecting 7% and 9% annual growth, which is supported by strong prescription demand but partially offset by lower net pricing tied to formulary access investments. Additionally, the report also shows that CRENESSITY contributed $135.3 million in Q4 sales and $301.2 million for the year, which is driven by robust patient enrollment and reimbursement coverage.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company developing treatments for neurological and endocrine-related disorders, focusing on innovative therapies for conditions like movement disorders, epilepsy, and hormonal diseases.

While we acknowledge the potential of NBIX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NBIX and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Unstoppable Dividend Stocks to Buy According to Analysts and Dividend Champions, Contenders and Challengers list: 15 Highest Yielding Stocks.

Disclosure: None.